The newly published report titled "Global COVID-19 Therapeutics Market– By Trends, Industry Competition Analysis, Clinical Trial/Pipeline Analysis, Revenue (US$ Billions) and Forecast Till 2030." of InsightAce Analytic Pvt. Ltd. features in-depth analysis and an extensive study on the market, exploring its significant factors.
According to the latest market intelligence research report by InsightAce Analytic, the global COVID-19 Therapeutics market size was valued at US$ 10.2 Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record a promising CAGR of 10.7% from 2021 to 2030.
COVID-19 is a contagious disease triggered by the most recently discovered coronavirus, which has affected millions of individuals worldwide. The coronavirus can be treated with various drugs, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. In August 2021, The World Health Organization (WHO) released a report that represents Artesunate, imatinib, and infliximab are three new potential medications being investigated in the latest phase of the global Solidarity clinical trials to find effective COVID-19 therapies. Additional medicines approved for emergency use include Eli Lilly and Company's monoclonal antibodies bamlanivimab with etesevimab; Regeneron's casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology's Xevudy (sotrovimab); Roche's Actemra; Celltrion's Regkirona; and convalescent plasma. The growth of the COVID-19 Therapeutics Market is primarily attributed the increased prevalence of COVID-19 across the globe. In the first week of January 2022, Covid-19 cases have now been recorded in over 300 million people worldwide. The United States had over 50 million confirmed cases and over 800,000 deaths, making it the Country with the highest death toll. Pharmaceutical companies are investing heavily in product research due to the rising pandemic effect, and they are focusing on the production of enhanced therapeutics that can cure the covid-19. The market is further supported by rising awareness about coronavirus and collective efforts by the pharmaceutical companies and government in the development of covid-19 therapeutic drugs.
The prominent players in the COVID-19 Therapeutics industry include:
Atea Pharmaceuticals, Inc., Fulcrum Therapeutics, CytoDyn, Eli Lilly and Company, Celltrion, Shanghai Junshi Biosciences Co., Ltd., NRX Pharmaceuticals, Veru Inc., Catalent, Inc., Humanigen, Inc., Molecular Partners AG, Cipla Limited, Merck, Regeneron Pharmaceuticals, Inc., Novartis International AG, Vir Biotechnology, Brii Biosciences Limited, Revive Therapeutics Ltd., GlaxoSmithKline plc, APEIRON Biologics AG, Janssen Pharmaceuticals, Bristol Myers Squibb, Trevena Inc, Constant Therapeutics LLC, Ono Pharmaceutical Co., Ltd., Amarin Corporation plc, NeuroBo Pharmaceuticals, Inc., FUJIFILM Toyama Chemical Co., Ltd., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, BioAegis Therapeutics, Pfizer, Takeda, Roivant Sciences, Celltex Therapeutics, Blade Therapeutics, A.I. Therapeutics, Inc., Marinomed Biotech AG, Synairgen, Romark Laboratories, SAb Biotherapeutics, Kiniksa Pharmaceuticals, UNION therapeutics A/S, and Other Prominent Players.
Key Industry Developments from Leading Players:
In Dec 2021, The U.S. Food and Drug Administration granted Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) an emergency use authorization (EUA) for the treatment of mild-to-moderate coronavirus illness (COVID-19) in adults and children.
In Nov 2021, Pfizer Inc. publicized its investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced death and hospitalization according to an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult high-risk patients
In Nov 2021, Merck and Ridgeback Biotherapeutics announced that ...
Read More
(All Rights Reserved)